We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Replimune Group Inc | NASDAQ:REPL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.37 | -6.23% | 5.57 | 5.36 | 5.90 | 6.00 | 5.47 | 5.86 | 762,717 | 22:36:32 |
Details of the presentations are as follows:
Abstract Title: Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)Session Type: Oral PresentationSession Title: Immunotherapy Session Date and Time: Sunday, April 7, 2024 at 1:00 pm EDTAbstract Number: 9269
Abstract Title: Enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumabSession Type: Poster PresentationSession Title: Immunomodulatory Interventions and MechanismsSession Date and Time: Monday, April 8, 2024 at 9:00 am EDTAbstract Number: 2467
About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries Chris BrinzeyICR Westwicke339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen GoldenbergReplimune917.548.1582media@replimune.com
1 Year Replimune Chart |
1 Month Replimune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions